论文部分内容阅读
目的研究舒利迭(50/500μg)在慢性阻塞性肺疾病稳定期治疗中肺功能/血气分析、不良反应的疗效观察。方法选择2009年6月~2010年4月在新疆医科大学第二附属医院呼吸科就诊COPD稳定期患者60例。患者均予持续低流量吸氧、抗感染、解痉平喘及止咳化痰等常规处理,治疗组给予舒利迭50/500μg,对照组给予舒利迭50/250μg治疗。观察6个月内两组患者治疗前、后的肺功能变化,检测6min步行距离、Borg呼吸困难评分,观察急性加重频数的发生、药物不良反应。结果两组治疗后肺功能水平均高于治疗前,差异具有统计学意义(P均<0.05);两组治疗后肺功能水平比较,治疗组肺功能改善好于对照组,差异具有统计学意义(P<0.05);两组患者在治疗后6 min步行距离、Borg呼吸困难评分均较治疗前明显改善,治疗组与对照组有明显差异,差异有统计学意义(P<0.05);两组治疗后急性加重频数的发生比较,对照组较治疗组低,差异有统计学意义(P<0.05);两组药物不良反应比较,差异无统计学意义(P>0.05)。结论长期应用舒利迭(50/500μg)治疗稳定期中、重度COPD患者,可提高患者肺功能、健康生活质量,可减少COPD急性加重频数,不良反应较小。
Objective To study the effect of seretide (50 / 500μg) on lung function / blood gas analysis and adverse reactions in the treatment of chronic obstructive pulmonary disease (COPD). Methods From June 2009 to April 2010, 60 patients with stable COPD were admitted to Respiratory Department of the Second Affiliated Hospital of Xinjiang Medical University. Patients were given continuous low-flow oxygen, anti-infection, anti-spasmodic asthma and cough and phlegm and other conventional treatment, the treatment group was given 50/50 μg of seretide, and the control group was given 50/50 μg of seretide treatment. The changes of lung function in two groups before and after treatment within 6 months were observed. The 6-minute walk distance, Borg dyspnea score, the occurrence of acute exacerbation frequency and the adverse drug reactions were observed. Results The lung function of the two groups after treatment was higher than before treatment, the difference was statistically significant (P all <0.05); two groups of lung function after treatment compared to the treatment group improved lung function better than the control group, the difference was statistically significant (P <0.05). The walking distance and Borg dyspnea score at 6 min after treatment in both groups were significantly improved compared with those before treatment, with significant difference between the treatment group and the control group (P <0.05) After treatment, the frequency of acute exacerbations was significantly lower in the control group than in the treatment group (P <0.05). There was no significant difference in adverse drug reactions between the two groups (P> 0.05). Conclusion Long-term use of seretide (50 / 500μg) in patients with stable and moderate COPD can improve lung function and quality of life of patients, reduce the frequency of acute exacerbations of COPD, and have a small adverse reaction rate.